Table 4 The extracted antidiabetic medication prescription data obtained in the retrospective cohort study

n

170

170

170

170

Sulfonylureas (%)

78 (46)

63 (37)

67 (39)

59 (35)

0.02*

Glimepiride (n)

12

31

54

47

Glimepiride^a (mg)

3 (2, 5.625) [1, 6]

3 (2, 4) [1, 6]

1.875 (1, 3) [0.5, 6]

1 (0.5, 2) [0.5, 6]

−0.45

<0.01

Biguanide (%)

78 (46)

83 (49)

84 (49)

76 (45)

0.76*

Metformin (n)

77

83

84

76

Metformin^a (mg)

750 (750, 750) [375, 750]

750 (750, 750) [250, 750]

750 (750, 750) [250, 1000]

750 (750, 1500) [250, 2250]

0.28

<0.01

Thiazolidine (%)

5 (3)

35 (21)

83 (49)

48 (28)

<0.01*

Pioglitazone^a (mg)

30 (30, 30) [30]

15 (15, 30) [7.5, 30]

15 (15, 30) [7.5, 45]

15 (15, 30) [7.5, 45]

0.06

0.16

α-GI (%)

54 (32)

56 (33)

60 (35)

43 (25)

0.30*

Voglibose (n)

43

50

52

37

Voglibose^a (mg)

0.9 (0.6, 0.9) [0.4, 0.9]

0.6 (0.6, 0.9) [0.2, 0.9]

0.9 (0.6, 0.9) [0.2, 0.9]

0.9 (0.6, 0.9) [0.3, 0.9]

0.26

<0.01

Meglitinides (%)

12 (7)

15 (9)

22 (13)

8 (5)

0.44*

Nateglinide (n)

12

15

19

6

Nateglinide^a (mg)

270 (270, 270) [270, 270]

270 (270, 270) [60, 270]

270 (180, 270) [60, 360]

135 (90, 225) [90, 360]

−0.18

0.01

DPP4I (%)

0 (0)

0 (0)

1 (1)

70 (41)

<0.01*

Sitagliptin (n)

0

0

1

52

Sitagliptin^a (mg)

50 (50, 50) [50, 50]

50 (25, 50) [25, 100]

0.09

0.30

Insulins (%)

69 (41)

96 (57)

97 (57)

93 (55)

<0.01*